瑞麗醫美(02135.HK)經調整年內溢利達2191萬元
格隆匯3月26日丨瑞麗醫美(02135.HK)公佈2020年度業績,期內集團收益為1.65億元人民幣(單位下同),毛利為801.71萬元,經調整年內溢利為2191.0萬元,母公司擁有人應占溢利425.1萬元,每股基本及攤薄盈利為0.25分。
於2020年度,集團醫療美容客户總數為73235名,較2019年度活躍客户人數69835名增加了4.9%;其中新客户數量為31841名,佔2020年度醫療美容客户總數的43.5%。
截至2020年12月31日止年度,集團的醫療美容機構擁有平均行業經驗超過十年的70名執業醫師。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.